NCT06354998View on ClinicalTrials.gov

A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

217

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

May 10, 2024

Study Completion Date

May 10, 2024

Conditions
SARS-CoV-2
Interventions
BIOLOGICAL

Investigational mRNA-1273.815

Sterile solution for injection

BIOLOGICAL

Licensed Spikevax Vaccine

Commercially available formulation

Trial Locations (7)

2010

Holdsworth House, Darlinghurst

2617

Paratus Canberra, Canberra

Paratus Brisbane, Brisbane

3021

AusTrials Sunshine Hospital, Melbourne

3124

Emeritus Melbourne, Camberwell

4101

University of the Sunshine Coast, South Bank, South Brisbane

4506

USC Morayfield, Morayfield

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY

NCT06354998 - A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults | Biotech Hunter | Biotech Hunter